DK2451844T3 - Tlr3-bindingsmidler - Google Patents

Tlr3-bindingsmidler Download PDF

Info

Publication number
DK2451844T3
DK2451844T3 DK10734092.9T DK10734092T DK2451844T3 DK 2451844 T3 DK2451844 T3 DK 2451844T3 DK 10734092 T DK10734092 T DK 10734092T DK 2451844 T3 DK2451844 T3 DK 2451844T3
Authority
DK
Denmark
Prior art keywords
antibody
tlr3
antibodies
amino acid
ser
Prior art date
Application number
DK10734092.9T
Other languages
English (en)
Inventor
Laurent Gauthier
Catherine Massacrier
Yannis Morel
Carine Paturel
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Application granted granted Critical
Publication of DK2451844T3 publication Critical patent/DK2451844T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)

Claims (15)

1. Monoklonalt antistof, der specifikt binder et humant TLR3-polypeptid, hvor antistoffet hæmmer signalering ved hjælp af TLR3-polypeptidet uden at blokere binding af en dsRNA-TLR3-ligand til TLR3-polypeptidet, hvor antistoffet binder specifikt til TLR3-polypeptidet under neutrale betingelser ved et pH på mellem 6,6 og 7,4 og under sure betingelser ved et pH på mellem 4,5 og 6,5 med en subnanomolær KD for dets bivalente bindingsaffinitet; hvor antistoffet konkurrerer om binding til et TLR3-polypeptid med et antistof, der er udvalgt fra gruppen, der består af: (a) et antistof med et VH- og VL-område ifølge henholdsvis SEQ ID NO: 34 og 35 og (b) et antistof med et VH- og VL-område ifølge henholdsvis SEQ ID NO: 2 og 3.
2. Antistof ifølge krav 1, hvor antistoffet binder specifikt til TLR3-polypeptidet under sure betingelser med en 100 pikomolær eller bedre KD for dets bivalente bindingsaffinitet.
3. Antistof ifølge krav 1 til 2, hvor antistoffet er udvalgt fra gruppen, der består af: (a) et antistof med (i) tung kæde-CDR 1, 2 og 3 (HCDR1, HCDR2, HCDR3)-aminosyresekvenserne ifølge henholdsvis SEQ ID NO: 4, 5 og 6 og (ii) let kæde-CDR 1, 2 og 3 (LCDR1, LCDR2, LCDR3) -aminosyresekvenserne ifølge henholdsvis SEQ ID NO: 7, 8 og 9; og (b) et antistof med (i) tung kæde-CDR 1, 2 og 3 (HCDR1, HCDR2, HCDR3)-aminosyresekvenserne ifølge henholdsvis SEQ ID NO: 36, 37 og 38 og (ii) let kæde-CDR 1, 2 og 3 (LCDR1, LCDR2, LCDR3) -aminosyresekvenserne ifølge henholdsvis SEQ ID NO: 39, 40 og 41.
4. Antistof ifølge krav 1 til 3, hvor antistoffet er et kimært, humant eller humaniseret antistof.
5. Antistof ifølge krav 4, hvor isotypen af antistoffet er et IgG4.
6. Antistof ifølge krav 1 til 5, hvor antistoffet omfatter et Fc-områder, der er modificeret til reducering af dets FcyR-binding.
7. Antistof ifølge krav 1 til 6, hvor antistoffet er et antistoffragment, der er udvalgt blandt Fab, Fab', Fab'-SH, F(ab')2/ Fv, diabodies, enkeltkædet antistoffragment eller et multispecifikt antistof, der omfatter mangfoldige forskellige antistoffragmenter.
8. Antistof ifølge krav 1 til 7, hvor antistoffet er konjugeret eller kovalent bundet til en toksisk del.
9. Antistof ifølge krav 1 til 8, hvor antistoffet er i stand til at blive internaliseret af en TLR3-udtrykkende celle.
10. Antistof ifølge krav 1 til 9, hvor antistoffet er konjugeret eller kovalent bundet til en påviselig del.
11. Antistof ifølge krav 1 til 10, hvor antistoffet er dannet ved immunisering af et non-humant dyr med et immunogen, der omfatter et TLR3-polypeptid.
12. Hybridom eller rekombinant værtscelle, der danner antistoffet ifølge krav 1 til 11.
13. Farmaceutisk præparat, der omfatter et antistof ifølge et hvilket som helst af kravene 1-11 og et farmaceutisk acceptabelt bæremateriale.
14. Farmaceutisk præparat ifølge krav 13 til anvendelse til behandling eller forebyggelse af en sygdom, der er udvalgt fra gruppen, der består af autoimmunitet, inflammation, allergi, astma, infektion, cirrose og sepsis.
15. Farmaceutisk præparat ifølge krav 13 til anvendelse til behandling eller forebyggelse af en cancer.
DK10734092.9T 2009-07-10 2010-07-09 Tlr3-bindingsmidler DK2451844T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22454809P 2009-07-10 2009-07-10
PCT/EP2010/059946 WO2011004028A2 (en) 2009-07-10 2010-07-09 Tlr3 binding agents

Publications (1)

Publication Number Publication Date
DK2451844T3 true DK2451844T3 (da) 2015-07-27

Family

ID=42727505

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10734092.9T DK2451844T3 (da) 2009-07-10 2010-07-09 Tlr3-bindingsmidler

Country Status (10)

Country Link
US (2) US9388246B2 (da)
EP (1) EP2451844B1 (da)
JP (1) JP5800809B2 (da)
CN (1) CN102471382A (da)
AU (1) AU2010270163B2 (da)
CA (1) CA2766747C (da)
DK (1) DK2451844T3 (da)
ES (1) ES2543095T3 (da)
RU (1) RU2562865C2 (da)
WO (1) WO2011004028A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8460659B2 (en) 2008-10-31 2013-06-11 Janssen Biotech, Inc. Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
KR101683033B1 (ko) 2008-10-31 2016-12-06 얀센 바이오테크 인코포레이티드 톨-유사 수용체 3 길항제
CN102245773B (zh) 2008-11-03 2014-08-27 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
AU2010270163B2 (en) 2009-07-10 2016-05-05 Innate Pharma, S.A. TLR3 binding agents
CA2824313A1 (en) * 2011-01-12 2012-07-19 Innate Pharma Tlr3 binding agents
BR112013025198A2 (pt) * 2011-03-31 2018-12-04 Alethia Biotherapeutics Inc. anticorpos contra antígeno 1 associado a rim e fragmentos de ligação a antígeno do mesmo
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
US9260531B2 (en) 2012-05-09 2016-02-16 Eli Lilly And Company Anti-c-met antibodies
DK2855527T3 (da) * 2012-05-31 2018-11-26 Innate Pharma Tlr3-bindemidler
CN107043424B (zh) * 2012-08-21 2021-03-16 詹森药业有限公司 利培酮的抗体及其用途
SG11201604503XA (en) 2013-12-03 2016-07-28 Agency Science Tech & Res Cytotoxic antibody
CA2959141A1 (en) * 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
US11111288B2 (en) 2014-08-28 2021-09-07 Bioatla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
US11254742B2 (en) 2016-05-13 2022-02-22 Bioatla, Inc. Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2021146383A1 (en) * 2020-01-17 2021-07-22 BioLegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
US20230348571A1 (en) * 2020-04-06 2023-11-02 Vanderbilt University Cross-reactive coronavirus antibodies and uses thereof
EP4301396A1 (en) * 2021-03-03 2024-01-10 The United States of America, as represented by the Secretary, Department of Health and Human Services La protien as a novel regulator of osteoclastogenesis

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AR006928A1 (es) 1996-05-01 1999-09-29 Pioneer Hi Bred Int Una molecula de adn aislada que codifica una proteina fluorescente verde como marcador rastreable para la transformacion de plantas, un metodo para laproduccion de plantas transgenicas, un vector de expresion, una planta transgenica y celulas de dichas plantas.
CA2289912C (en) 1997-05-07 2011-07-26 Schering Corporation Human receptor proteins; related reagents and methods
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
KR100923514B1 (ko) 2000-12-28 2009-10-27 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
EP1576013A4 (en) 2002-03-22 2008-08-13 Amrad Operations Pty Ltd MONOCLONAL ANTIBODY AGAINST THE INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13RA1)
JP2004016021A (ja) 2002-06-12 2004-01-22 Japan Science & Technology Corp 抗体および阻害剤並びにそれを用いた形質転換方法および形質転換キット
US20050180972A1 (en) 2002-07-31 2005-08-18 Wahl Alan F. Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders
TWI487535B (zh) * 2004-11-30 2015-06-11 Centocor Inc 類鐸受體３（ｔｏｌｌ ｌｉｋｅ ｒｅｃｅｐｔｏｒ３）拮抗劑，方法及用途
ES2435775T3 (es) * 2005-10-27 2013-12-23 Janssen Biotech, Inc. Moduladores de receptor tipo Toll 3, procedimientos y usos
KR101373464B1 (ko) 2005-12-08 2014-03-14 메다렉스, 엘.엘.시. 단백질 티로신 키나제 7(ｐｔｋ7)에 대한 인간 단일클론항체 및 그의 용도
US8354508B2 (en) 2006-07-21 2013-01-15 Diadexus, Inc. PRO115 antibody compositions and methods of use
AU2007310838A1 (en) 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
EP2155249A4 (en) 2007-05-15 2011-11-16 Oncomed Pharm Inc COMPOSITIONS AND METHOD FOR DIAGNOSIS AND TREATMENT OF CANCER
EP2281043B1 (en) 2008-04-25 2013-03-13 Innate Pharma Improved tlr3 agonist compositions
US20130090457A1 (en) 2008-10-31 2013-04-11 Janssen Biotech, Inc. Toll-Like Receptor 3 Antagonists for the Treatment of Metabolic and Cardiovascular Diseases
US8460659B2 (en) 2008-10-31 2013-06-11 Janssen Biotech, Inc. Toll-like receptor 3 antagonists for the treatment of metabolic and cardiovascular diseases
KR101683033B1 (ko) 2008-10-31 2016-12-06 얀센 바이오테크 인코포레이티드 톨-유사 수용체 3 길항제
DK2425008T3 (da) 2009-04-29 2015-10-05 Janssen Biotech Inc Toll-lignende receptor 3-antagonister
AU2010270163B2 (en) 2009-07-10 2016-05-05 Innate Pharma, S.A. TLR3 binding agents
ES2438774T3 (es) 2009-12-11 2014-01-20 Deutsches Krebsforschungszentrum Anticuerpo que se une a parvovirus H-1
CA2824313A1 (en) 2011-01-12 2012-07-19 Innate Pharma Tlr3 binding agents
DK2855527T3 (da) 2012-05-31 2018-11-26 Innate Pharma Tlr3-bindemidler

Also Published As

Publication number Publication date
ES2543095T3 (es) 2015-08-14
EP2451844B1 (en) 2015-04-22
US9388246B2 (en) 2016-07-12
RU2562865C2 (ru) 2015-09-10
JP2012532851A (ja) 2012-12-20
CN102471382A (zh) 2012-05-23
AU2010270163A1 (en) 2012-02-02
CA2766747C (en) 2019-04-02
US20160347853A1 (en) 2016-12-01
US20120034232A1 (en) 2012-02-09
WO2011004028A2 (en) 2011-01-13
AU2010270163B2 (en) 2016-05-05
RU2012103212A (ru) 2013-08-20
EP2451844A2 (en) 2012-05-16
JP5800809B2 (ja) 2015-10-28
WO2011004028A3 (en) 2011-05-19
WO2011004028A9 (en) 2011-08-11
CA2766747A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
DK2451844T3 (da) Tlr3-bindingsmidler
JP7132981B2 (ja) Ｃｄ７３遮断
CN110382536B (zh) 抗pd-1抗体及其用途
JP7274469B2 (ja) Ｃｄ３９／ｃｄ７３軸によるｔ細胞活性の回復
KR102022734B1 (ko) 신규 조절제 및 용법
DK2817338T3 (da) DLL3-modulatorer og fremgangsmåder til anvendelse
AU2011293127B2 (en) Notum protein modulators and methods of use
EP3259288A1 (en) Cd73 blockade
US20180030144A1 (en) Cd73 blockade
KR20140031175A (ko) 신규 조절제 및 용법
CA3004972A1 (en) Siglec-10 antibodies
TWI853077B (zh) 新型抗ｃｄ３９抗體
BR112017006464B1 (pt) Anticorpo isolado, composição farmacêutica, uso de um anticorpo e anticorpo